What does PT-141 do?

Sexual arousal starts in your brain, not your genitals. PT-141 acts on melanocortin receptors (MC3R and MC4R) in the hypothalamus — the brain area that regulates sexual desire, among other functions. By activating these receptors, it increases the neural signal for sexual desire and arousal.

This is fundamentally different from how Viagra works. Viagra improves blood flow to achieve and maintain an erection, but does nothing for desire. If your issue is "I can physically perform but I don’t feel desire," PT-141 addresses that specific problem.

In clinical trials for HSDD in women, PT-141 significantly improved desire scores compared to placebo. In men, it’s been studied for erectile dysfunction — including in men who didn’t respond to PDE5 inhibitors — with positive results.

Who uses it?

• Women with HSDD — the FDA-approved indication (as Vyleesi)
• Men with desire issues — when the problem is low desire rather than vascular erectile dysfunction
• PDE5 inhibitor non-responders — men who don’t respond to Viagra/Cialis
• Couples — used as-needed before sexual activity

What to know before trying

Timing: Inject subcutaneously about 45 minutes before anticipated sexual activity. Effects last 6–12 hours. Do not use more than once in 24 hours, and no more than 8 doses per month (per FDA label).

Not for daily use: PT-141 is used as-needed, not as a daily supplement. Repeated frequent use can cause melanocortin receptor desensitisation.

Blood pressure: PT-141 can cause a transient blood pressure increase. People with uncontrolled hypertension or cardiovascular disease should use it only under physician supervision.

Frequently Asked Questions

How it works in your body

PT-141 is a cyclic heptapeptide derived from the melanocortin peptide α-MSH. It activates MC3R and MC4R receptors in the hypothalamus, areas of the brain involved in sexual behaviour, appetite, and energy homeostasis. This activation triggers downstream signalling that increases sexual desire and arousal independently of the vascular system. The mechanism explains why it works in people for whom PDE5 inhibitors (which only address blood flow) are ineffective.

What the studies show

• HSDD in women: Two Phase III trials (RECONNECT) showed statistically significant improvement in desire and reduction in distress vs placebo. Led to FDA approval as Vyleesi.
• Erectile dysfunction in men: Phase II trials showed positive effects, including in PDE5 inhibitor non-responders
• Mechanism: Central (brain) rather than peripheral (vascular) — fundamentally different from PDE5 inhibitors

What to monitor

• Blood pressure — check before and after first use; PT-141 can cause transient increases
• Skin pigmentation — melanocortin activation can darken skin (especially injection sites). Monitor for unexpected changes.
• Frequency of use — limit to ≤8 doses per month to prevent receptor desensitisation

Side effects & safety

PT-141 has well-characterised side effects from its clinical trial programme:

• Nausea — the most common and often most significant side effect (~40% of users). Can be substantial with first use. Improves with subsequent doses. Anti-emetics help.
• Flushing — facial flushing and warmth, typically within 30 minutes of injection. Transient.
• Injection site reactions — redness, bruising, or irritation at injection site.
• Blood pressure increase — transient elevation in blood pressure. Usually small but relevant for people with hypertension or cardiovascular disease.
• Skin darkening — melanocortin pathway activation can cause hyperpigmentation, particularly at injection sites or in sun-exposed areas.
• Headache — reported by some users. Usually mild.

Who should avoid it: People with uncontrolled hypertension, cardiovascular disease, pregnant women, and anyone on medications that affect blood pressure. Limit use to ≤8 times per month.

Related